GeneDx is trading 12% up at $76.00 after reporting second-quarter 2026 revenue of $114.4 million, beating analyst estimates and returning to adjusted profitability.
- Revenue grew 11% year-over-year, supported by a 32% surge in exome and genome test volumes.
- Management reaffirmed full-year 2026 revenue guidance of $475 million to $490 million.
- The improved profitability profile and positive outlook are driving strong after-hours demand for the stock.